Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 20/20 | 1.00 |
| ▸ | DRD2 | P14416 | 19/20 | 1.00 |
| ▸ | HTR1A | P08908 | 12/20 | 1.00 |
| ▸ | HTR2A | P28223 | 12/20 | 1.00 |
| ▸ | HTR2C | P28335 | 10/20 | 1.00 |
| ▸ | DRD4 | P21917 | 9/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | DRD1 | P21728 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16140180 | 0.91 | DRD3 (0.83) | DRD3DRD2HTR1AHTR2AHTR2C | |
| SCHEMBL3088535 | 0.88 | DRD3 (1.00) | DRD3DRD2HTR1AHTR2AHTR2C | |
| SCHEMBL13998964 | 0.88 | DRD2 (0.78) | DRD3DRD2HTR1AHTR2AHTR2C | |
| SCHEMBL3086679 | 0.86 | DRD3 (1.00) | DRD3DRD2HTR1AHTR2AHTR2C | |
| SCHEMBL29730963 | 0.85 | DRD3 (1.00) | DRD3DRD2HTR1AHTR2AHTR2C | |
| SCHEMBL3080465 | 0.85 | DRD3 (1.00) | DRD3DRD2HTR1AHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL29634904 | 0.84 | DRD3 (0.97) | DRD3DRD2HTR1AHTR2AHTR2C | |
| SCHEMBL29730842 | 0.81 | DRD2 (1.00) | DRD3DRD2HTR1AHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL19411207 | 0.80 | DRD2 (0.98) | DRD3DRD2HTR1AHTR2AHTR2C | |
| SCHEMBL13094432 | 0.78 | DRD2 (1.00) | DRD3DRD2HTR1AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296249-A1 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296249-A1 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296249-A1 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-10-02 | — | — | US | disclosed |
| US-8748608-B2 | 4-phenylpiperazine derivatives with functionalized linkers as dopamine D3 receptor selective ligands and methods of use | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748608-B2 | 4-phenylpiperazine derivatives with functionalized linkers as dopamine D3 receptor selective ligands and methods of use | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748608-B2 | 4-phenylpiperazine derivatives with functionalized linkers as dopamine D3 receptor selective ligands and methods of use | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-06-10 | — | — | US | disclosed |
| US-20100267737-A1 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | THE GOV. OF THE U.S.A AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH AND HUMAN SERVICES | 2010-10-21 | — | — | US | disclosed |
| US-20100267737-A1 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | THE GOV. OF THE U.S.A AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH AND HUMAN SERVICES | 2010-10-21 | — | — | US | disclosed |
| US-20100267737-A1 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | THE GOV. OF THE U.S.A AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH AND HUMAN SERVICES | 2010-10-21 | — | — | US | disclosed |
| WO-2008153573-A1 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008153573-A1 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267737-A1 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | DRD3, DRD2, HTR3C | DRD3 1/4885DRD2 2/4885HTR1A 192/4885 |
| US-20140296249-A1 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | DRD3, DRD2, SLC6A3 | DRD3 1/4885DRD2 2/4885HTR1A 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.